A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo controlled, four-arm, dose-ranging study. The
purpose is to evaluate the relationship between the dose of lebrikizumab and the response in
terms of the efficacy, safety, and tolerability in patients with asthma who are not on
inhaled steroids.